Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China
Liu Liu,Yan Wei,Yue Teng,Juntao Yan,Fuming Li,Yingyao Chen
DOI: https://doi.org/10.2147/PPA.S344622
2022-02-04
Patient Preference and Adherence
Abstract:Liu Liu, 1, 2 Yan Wei, 1, 2 Yue Teng, 1– 3 Juntao Yan, 1, 2 Fuming Li, 1, 2 Yingyao Chen 1, 2 1 School of Public Health, Fudan University, Shanghai, People's Republic of China; 2 NHC Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, People's Republic of China; 3 Department of Outpatient, Shanghai Research Institute of Acupuncture and Meridian, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China Correspondence: Yan Wei NHC Key Laboratory of Health Technology Assessment, School of Public Health, Fudan University, Shanghai, People's Republic of China , Tel +86 18930749707 , Email Purpose: To assess health-related quality of life (HRQoL) and utility scores of lung cancer patients treated with traditional Chinese medicine (TCM) in China. Methods: This cross-sectional study included lung cancer patients treated with TCM in seven tertiary hospitals in Shanghai, China. The HRQoL and utility scores of these patients were measured using the five-level EQ-5D (EQ-5D-5L). The EQ-5D-5L utility scores were derived from the Chinese EQ-5D-5L Value Set. The relationships between HRQoL and the socio-demographic and clinical characteristics of these patients were further explored by Tobit regression. Results: This study included a total of 347 patients. Their mean ± SD and median EQ-5D-5L utility scores were 0.851 ± 0.198 and 0.893, respectively. The highest proportion of participants reporting problems was observed in pain/discomfort dimension (57.9%) and anxiety/depression (45.5%). Lung cancer patients treated with TCM had poor HRQoL, influenced by cancer clinical stage. Conclusion: Lung cancer patients treated with TCM have poor HRQoL, with many patients reporting problems in the pain/discomfort and anxiety/depression dimensions. The information on health utility scores and HRQoL of lung cancer patients treated with TCM could be useful for future supportive care, economic evaluations and decision-making in China. Keywords: lung cancer, health-related quality of life, traditional Chinese medicine, EQ-5D-5L Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths, both worldwide 1 and in China. 2 In 2015, 787,000 patients in China were newly diagnosed with lung cancer and 631,000 patients died of this disease, accounting for 20.03% of patients diagnosed with cancer and 26.99% who died of cancer during that year. 3 In addition, the burden of lung cancer has increased in the past three decades. Lung cancer is one of the most aggressive malignant tumors, with a 5-year overall survival (OS) rate of about 19.7%, 4 much lower than the 5-year OS rate of 40.5% among all cancer patients in China. 3 In the treatment process, patients with lung cancers will suffer from the disease's malignant degree and its therapy toxicity. 5 At present, the leading treatment methods for lung cancer patients include surgery, chemotherapy, radiotherapy, and targeted therapy. Traditional Chinese Medicine (TCM), which has a long history in China, has been widely used to treat various diseases including lung cancer in China and other Asian countries or areas. 6–8 In addition to their physical symptoms, lung cancer patients frequently experience depression and anxiety, 9,10 having a negative impact on their health-related quality of life (HRQoL). HRQoL, especially preference-based health-related QoL, has become an increasingly important outcome measure in the cost-utility analysis (CUA), a particular form of economic evaluation. 11 HRQoL can inform patient management and policy decisions, making it important to measure HRQoL. 12 Although many studies in patients with lung cancer have investigated their HRQoL after surgery, 13 radiotherapy, 14 and/or chemotherapy, 15–17 few studies to date have evaluated their HRQoL after TCM treatment, which measured by disease-specific instruments, including the Functional Assessment of Cancer Therapy-Lung (FACT-L), 18,19 the quality-of-life (QoL) instrument for lung cancer based on Traditional Chinese Medicine (QLASTCM-Lu), 20,21 and European Organization for Research and the Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and EORTC QLQ-LC13). 22,23 Although these methods are valid and reliable, they are not preference-based instruments to elicit health utility scores for lung cancer patients. The present study, therefore, aimed to assess the HRQ -Abstract Truncated-
medicine, general & internal